Partners in the UK-based innovative alternative health company, Sweet Cures of York, are leading a demand for drug trials to also test against natural remedies, both new and traditional, as well as placebo. The information revealed would be invaluable to
Americas Watchdog is one of the premier consumer advocacy groups in the United States. Because of numerous horror story's in the national press, about the drug called Trasylol, Americas Watchdog has initiated a national investigation focused on this drug. The
Confidential Alcohol Recovery Program - Freedomfromalcohol.Com - Offers Hope and Rehabilitation from Problem Drinking. Distinguished Alcohol Addiction Expert Michael Pearlman, M.D. Has Successfully Assisted Hundreds of Patients With His Proven Alcohol Treatment Method. (PRWeb Apr 2, 2008) Read the full
Americas Watchdog is launching a U.S. investigation involving the effectiveness of the cholesterol medications called Vytorin and Zetia. The question becomes, were these drugs as effective as portrayed on national television advertising? According to news reports released on March 31,
Encorium Group has signed a $1.6 million contract with Protherics, a UK biopharmaceutical company, for a Phase II trial of its novel immunotherapeutic vaccine, Angiotensin therapeutic vaccine, for the treatment of hypertension.
Adventrx Pharmaceuticals has reported that preclinical results of ANX-201, the company's broad-spectrum antiviral product candidate, demonstrate a unique resistance profile for ANX-201 and suggest suppression of resistance to nucleoside reverse transcriptase inhibitors, a commonly used class of drugs to treat
DRI Capital and Nanogen have entered into an agreement for DRI to acquire, for $10 million, all future royalties generated by Applied Biosystems under a license ABI has taken from Nanogen for MGB technology.
Pfizer has reported that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The enantiomer patent expires in July 2010.
BioAlliance Pharma has entered into an exclusive licensing agreement under which Korea-based Handok Pharmaceuticals will receive commercialization rights for Loramyc in Korea, Taiwan, Singapore and Malaysia.
A study conducted by the Harvard University revealed that the drugs fast-tracked by FDA are three times more likely to be withdrawn later than medicines approved at normal speed, reported the PharmaTimes.
Synergetics USA has announced that it will close its Philadelphia plant and merge the operations and production of generator products into its plant in O'Fallon Missouri.
Genta has reported that the Data Safety Monitoring Board for Agenda, a Phase III trial of Genasense injection, has recommended that the trial be continued as originally planned after initial review of blinded safety data from the study.
Cytokinetics has presented encouraging non-clinical data of CK-1827452, a novel small molecule activator of cardiac myosin, which is being evaluated in clinical trials for the potential treatment of heart failure.
Global Med Technologies, a medical information technology company, has signed a purchase agreement to acquire Inlog and it's German and related subsidiaries, for a maximum of $11.5 million in a combination of cash, stock and earnout.
Abbott has reported new data from two Phase III studies which showed that in patients with multiple lipid problems, the company's TriLipix combined with two commonly prescribed statins, significantly improved three key lipids, compared to the corresponding monotherapies.
King Pharmaceuticals has presented the encouraging results of its pivotal Phase III clinical trials evaluating CorVue, a selective adenosine A2a receptor agonist that the company is developing for cardiac pharmacologic stress imaging.
Takeda Pharmaceuticals Europe has reported new data from a clinical trial which showed that Actos has reduced the atherosclerotic burden in the coronary arteries compared to the sulphonylurea glimepiride, and prevented progression compared to baseline in patients living with type
The Immune Tolerance Institute has announced a collaboration with Beckman Coulter to establish a Center for Critical Path Immunology to investigate the role of the human immune system in disease.
